InfuSystem Holdings, Inc

Listed Company

INFUCIK 0001337013NYSEAcceleratedSmaller ReportingSurgical & Medical Instruments & ApparatusDelawareFY ends Dec 31

Period

FY 2025

Revenue

$143.44M

Net Income

$6.63M

Total Assets

$100.56M

Equity

$57.33M

Shares Out

20.18M

Op. Cash Flow

$24.41M

INFU$8.91+65.31% · past yearDBEQ Basic

Daily closing prices

Business

InfuSystem Holdings, Inc. is a national healthcare service provider offering durable medical equipment (DME) and related services to hospitals, oncology practices, ambulatory surgery centers, and other alternate site providers. The company operates two business platforms: Patient Services, which provides clinic-to-home infusion pump solutions primarily for oncology chemotherapy, and Device Solutions, which offers equipment rental, sales, consumables, and biomedical support services. InfuSystem serves approximately 2,100 outpatient oncology clinics across the United States and Canada through relationships with nearly 840 third-party payer networks.

Summary from 10-K filed 2026-02-27

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Net revenues	143	135	126	110	102
Cost of revenues	63	64	63	49	44
Gross profit	80	70	63	61	59
Amortization of intangibles	900,000	1	1	3	4
Selling and marketing	10	11	13	12	11
General and administrative	57	51	45	44	41
Total selling, general and administrative	68	64	59	59	56
Operating income	12	7	4	2	3
Interest expense	−1	−2	−2	—	—
Other income (expense)	2,000	−55,000	−67,000	−122,000	−186,000
Income (Loss) before income taxes	11	5	2	130,000	1
Provision for income taxes	−4	−3	−979,000	−112,000	163,000
Net income	7	2	872,000	18,000	1
Basic (in dollars per share)	0.32	0.11	0.04	0	0.07
Diluted (in dollars per share)	0.31	0.11	0.04	0	0.06
Basic (in shares)	21	21	21	21	21
Diluted (in shares)	21	22	22	22	22
Unrealized gain (loss) on hedges	−733,000	40,000	−523,000	2	355,000
(Provision for) benefit from income tax on unrealized hedge gain (loss)	179,000	−9,000	122,000	−388,000	−87,000
Other comprehensive income (loss)	−554,000	31,000	−401,000	1	268,000
Net comprehensive income	6	2	471,000	1	2

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	3	527,000	231,000	165,000	186,000
Accounts receivable, net	23	21	20	17	15
Inventories, net	5	7	6	5	4
Other current assets	5	4	4	3	3
Total current assets	36	32	31	25	22
Medical equipment for sale or rental	5	3	3	3	2
Medical equipment in rental service, net of accumulated depreciation	34	39	35	39	40
Property & equipment, net of accumulated depreciation	3	4	4	4	5
Goodwill	4	4	4	4	4
Intangible assets, net	7	6	7	8	11
Operating lease right of use assets	4	5	7	4	4
Deferred income taxes	5	7	9	10	10
Derivative financial instruments	748,000	1	1	2	355,000
Other assets	2	878,000	2	80,000	116,000
Total assets	101	104	103	99	98
Accounts payable	11	10	8	8	8
Other current liabilities	9	8	8	6	5
Total current liabilities	20	18	16	14	13
Long-term debt, net of current portion	20	24	29	33	33
Operating lease liabilities, net of current portion	3	5	6	4	4
Total liabilities	43	46	51	51	49
Preferred stock, $0.0001 par value: authorized 1,000,000 shares; none issued	0	0	0	0	0
Common stock, $0.0001 par value: authorized 200,000,000 shares; 20,209,636 shares issued and outstanding as of December 31, 2025 and 21,272,351 shares issued and outstanding as of December 31, 2024	2,000	2,000	2,000	2,000	2,000
Additional paid-in capital	117	114	110	106	102
Accumulated other comprehensive income	565,000	1	1	1	268,000
Retained deficit	−61	−57	−59	−59	−54
Total stockholders equity	57	58	52	48	48
Total liabilities and stockholders equity	101	104	103	99	98

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Provision for doubtful accounts	200,000	−167,000	−261,000	87,000	77,000
Depreciation	12	12	12	11	10
Loss on disposal of and reserve adjustments for medical equipment	519,000	942,000	2	2	1
Gain on sale of medical equipment	−3	−2	−3	−2	−3
Amortization of deferred debt issuance costs	81,000	78,000	120,000	73,000	151,000
Stock-based compensation	4	4	4	4	6
Deferred income taxes	3	2	633,000	19,000	−153,000
Accounts receivable	263,000	−701,000	−2	−1	829,000
Inventories	1	−126,000	−2	−882,000	−864,000
Other current assets	−903,000	202,000	−1	−387,000	−133,000
Other assets	114,000	2	−3	−135,000	−161,000
Accounts payable and other liabilities	−708,000	−676,000	2	3	−2
NET CASH PROVIDED BY OPERATING ACTIVITIES	24	20	11	18	18
Acquisition of business	−1	0	0	0	−8
Purchase of medical equipment	−8	−17	−10	−14	−16
Purchase of property and equipment	−560,000	−1	−1	−982,000	−980,000
Proceeds from sale of medical equipment, property and equipment	3	5	4	4	3
NET CASH USED IN INVESTING ACTIVITIES	−7	−13	−7	−11	−21
Principal payments on long-term debt	−52	−56	−55	−42	−82
Cash proceeds from long-term debt	48	51	52	42	76
Debt issuance costs	−197,000	0	−229,000	0	−386,000
Common stock repurchased as part of share repurchase program	−10	−1	−153,000	−5	−560,000
Common stock repurchased to satisfy statutory withholding on employee stock-based compensation plans	−1	−816,000	−1	−1	−1
Cash proceeds from exercise of options and ESPP	335,000	387,000	1	1	1
NET CASH USED IN FINANCING ACTIVITIES	−15	−7	−4	−6	−6
Net change in cash and cash equivalents	3	296,000	66,000	−21,000	−9
Cash paid for interest	1	2	2	1	1
Cash paid for income taxes	543,000	753,000	213,000	153,000	171,000
Additions to medical equipment and property	3	1	249,000	2	2

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro

Frequently asked questions

What is InfuSystem Holdings, Inc's CIK number?

InfuSystem Holdings, Inc's SEC CIK number is 0001337013 (1337013). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.

Where can I find InfuSystem Holdings, Inc's SEC filings?

All of InfuSystem Holdings, Inc's EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.

When did InfuSystem Holdings, Inc last report earnings?

InfuSystem Holdings, Inc (INFU) most recently filed an earnings 8-K with the SEC on May 7, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001628280-26-031649). This is InfuSystem Holdings, Inc's most recent earnings filing of record — not a forecast of its next earnings date.

What is InfuSystem Holdings, Inc's most recent earnings 8-K?

InfuSystem Holdings, Inc's latest earnings 8-K (Item 2.02) was filed May 7, 2026 under accession 0001628280-26-031649. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.

View InfuSystem Holdings, Inc's latest earnings 8-K →
Look up any company's CIK number →